Stocks › PTHS
Pelthos Therapeutics Inc.
PTHS·NYSE·
United States·USD
United States·USD$21.48
+0.98 (+4.78%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
PTHS
Pelthos Therapeutics Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
PTHSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of PTHS by members of U.S. Congress · 0 on record
No congressional trades in PTHS on record.
Whale Activity
Position changes in PTHS reported for 2026-06-30 by 4 tracked institutional filers
- Increased1
- New2
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 97.1K | $2.7M | increased |
| Knott David M Jr | 22.1K | $624K | — |
| CITADEL ADVISORS LLC | 15.0K | $425K | new |
| BlackRock, Inc. | 5,324 | $150K | new |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by PTHS insiders, by quarter · Form 4
Recent Insider Transactions
52 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Greenleaf PeterDirector · Director | Sale | −797 | $21.17 | $17K | Oct 2, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector · Director | Sale | −558 | $20.72 | $12K | Oct 2, 2026 | Form 4 ↗ |
| Pauls MatthewDirector · Director | Sale | −786 | $21.00 | $17K | Oct 2, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector · Director | Sale | −534 | $26.03 | $14K | Jul 2, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector · Director | Sale | −24 | $27.33 | $656 | Jul 2, 2026 | Form 4 ↗ |
| Pauls MatthewDirector · Director | Sale | −94 | $27.36 | $3K | Jul 2, 2026 | Form 4 ↗ |
| Pauls MatthewDirector · Director | Sale | −692 | $26.00 | $18K | Jul 2, 2026 | Form 4 ↗ |
| Greenleaf PeterDirector · Director | Sale | −85 | $27.27 | $2K | Jul 2, 2026 | Form 4 ↗ |
| Greenleaf PeterDirector · Director | Sale | −712 | $26.00 | $19K | Jul 2, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector | Sale | −59 | $27.94 | $2K | Jun 15, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector | Sale | −224 | $27.12 | $6K | Jun 15, 2026 | Form 4 ↗ |
| Davis Todd CDirector | Purchase | +503 | $28.73 | $14K | Jun 11, 2026 | Form 4 ↗ |
| Davis Todd CDirector | Purchase | +35.4K | $27.80 | $985K | Jun 11, 2026 | Form 4 ↗ |
| Francis Knuettel IICFO, Treas & Secty | Sale | −1,500 | $26.84 | $40K | May 22, 2026 | Form 4 ↗ |
| Francis Knuettel IICFO, Treas & Secty | Disposition to issuer | −13.9K | $0.00 | $0 | May 22, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector | Tax withholding | −144 | $27.01 | $4K | May 14, 2026 | Form 4 ↗ |
| Malamut RichardDirector | Sale | −280 | $21.36 | $6K | Apr 2, 2026 | Form 4 ↗ |
| Malamut RichardDirector | Sale | −310 | $20.51 | $6K | Apr 2, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector | Sale | −265 | $21.36 | $6K | Apr 2, 2026 | Form 4 ↗ |
| Friedberg Ezra MDirector | Sale | −293 | $20.51 | $6K | Apr 2, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding PTHS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 78.0K | $2.2M | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 16.1K | $456K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 7,464 | $198K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 4,991 | $141K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 2,052 | $54K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 1,972 | $52K | 0.00% | May 31, 2026 |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 1,818 | $51K | 0.00% | Jun 30, 2026 |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 1,180 | $33K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 333 | $9K | 0.00% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list PTHS's shares (CUSIP 171126204), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Neil ShahrestaniSCHEDULE 13G/A · passive (13G) · 256.6K shares7.7%
May 15, 2026 · ↗ - Ikarian Capital, LLCSCHEDULE 13G/A · passive (13G) · 256.6K shares7.7%
May 15, 2026 · ↗ - Maier Joshua TarlowSCHEDULE 13G/A · passive (13G) · 337.0K shares9.9%
May 7, 2026 · ↗ - 3i Management LLCSCHEDULE 13G/A · passive (13G) · 337.0K shares9.9%
May 7, 2026 · ↗ - 3i, LPSCHEDULE 13G/A · passive (13G) · 337.0K shares9.9%
May 7, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Pelthos Therapeutics Inc. as client
No lobbying filings found naming Pelthos Therapeutics Inc. as the client.
Government Contracts
Federal awards to Pelthos Therapeutics Inc. · USAspending
No federal contract awards found for Pelthos Therapeutics Inc..
U.S. Patents
Recent USPTO applications naming Pelthos Therapeutics Inc.
No USPTO patent applications found for Pelthos Therapeutics Inc..
Annual Financials
From PTHS's 10-K filings · XBRL
No annual XBRL figures on record for PTHS. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-10Reverse splitJul 2, 2025
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteOct 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 13, 2026
EDGAR ↗ - 8-K · Items 4.02Non-reliance on financialsAug 13, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureMay 28, 2026
EDGAR ↗ - 8-K · Items 4.01, 5.02, 9.01Change in auditor · Officer / director changeMay 21, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 14, 2026
EDGAR ↗
About Pelthos Therapeutics Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDURHAM, NC
IncorporatedNV
SEC CIK0001919246 ↗
Former namesChannel Therapeutics Corp, Chromocell Therapeutics Corp